The short version of size-exclusion chromatography fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-09 and is reviewed periodically as new material appears.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Research-grade material circulates through suppliers that differ widely in documentation and testing practice, so a certificate of analysis is a starting point rather than proof of quality. Independent verification typically repeats chromatographic purity and mass confirmation on the received lot, and compares results against a retained reference standard. Regulatory status varies by jurisdiction, and a substance cleared as a medicine is not interchangeable with a research chemical of the same name. Open questions include how closely non-pharmaceutical lots match approved material in impurity profile and in aggregate content.
Solid tirzepatide is handled as a lyophilised, hygroscopic peptide powder that should be kept desiccated, protected from light, and stored frozen, typically at or below minus twenty degrees Celsius for long-term retention. Material left at ambient temperature for extended periods can take up moisture, which promotes aggregation and deamidation. Commercial liquid presentations are kept refrigerated between two and eight degrees Celsius and are not frozen. Reconstituted laboratory solutions are generally held cold and used within a short window because hydrolysis and oxidation continue slowly in solution.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography for the main peak and with mass spectrometry for the observed molecular mass. Peptide mapping after enzymatic digestion confirms the primary sequence, while amino acid analysis provides a quantitative composition check. Size-exclusion chromatography and ion-exchange chromatography are used to look for aggregates and charge variants. Water content, residual solvents, and counter-ion content are measured separately, since a lyophilised powder is often reported on an as-is basis unless a correction is applied.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
=== Accelerated consumer adoption === The pandemic dramatically increased public awareness of diagnostic testing and normalized at-home health monitoring. Self-testing kits for COVID-19 familiarized millions of consumers with the concept of collecting samples at home, reducing barriers to adoption of other DTC testing services. The blood sample segment dominated the self-testing market with approximately 35.19% revenue share in 2024.
=== Names === Hydromorphone is known in various countries around the world by the brand names Hydal, Dimorphone, Exalgo, Sophidone LP, Dilaudid, Hydrostat, Hydromorfan, Hydromorphan, Hymorphan, Laudicon, Opidol, Palladone, Hydromorph Contin, and others. An extended-release version of hydromorphone, called Palladone, was available for a short time in the United States before being voluntarily withdrawn from the market after a July 2005 FDA advisory warned of a high overdose potential when taken with alcohol. As of March 2010, it is still available in Nepal under the brand name Opidol, in the United Kingdom under the brand name Palladone SR, and in most other European countries. There has also been a once-daily prolonged release version of hydromorphone available in Australia under the brand name Jurnista as of May 2009.
==== European Union ==== Danish pharmaceutical company Lundbeck has licensed nalmefene from Biotie Therapies and performed clinical trials with nalmefene for treatment of alcohol dependence. In 2011, they submitted an application for their medication named Selincro to the European Medicines Agency. The medication was authorized for use in the EU in March 2013. and in October 2013, Scotland became the first country in the EU to prescribe the drug for alcohol dependence. England followed Scotland by offering the medication as a treatment for problem drinking in October 2014. In November 2014, nalmefene was approved as a possible treatment supplied by Britain's National Health Service (NHS) for reducing alcohol consumption in people with alcohol dependence.
=== Axon terminal === Each corpuscle is associated with a myelinated axon; these are some of the largest and fastest-conducting sensory axons arising from the skin. Towards the center of the corpuscle, the axon loses its sheaths, ending as with a slight bulge at the center of the corpuscle. This axon terminal issues brief projections of unknown functional significance into gaps between the surrounding innermost lamellae; large mitochondria and small vessels aggregate near these projections.
If a cleft palate is present, the repair normally takes place at 9–12 months old. Before surgery, a polysomnography with a palatal plate in place is needed. This may predict the postoperative situation and gives insight on the chance of the presence of sleep apnea (OSAS) after the operation. Hearing loss is treated by bone conduction amplification, speech therapy, and educational intervention to avoid language/speech problems. The bone-anchored hearing aid is an alternative for individuals with ear anomalies. Zygomatic and orbital reconstruction is performed when the cranio-orbitozygomatic bone is completely developed, usually at the age of 5–7 years. In children, an autologous bone graft is mostly used. In combination with this transplantation, lipofilling can be used in the periorbital area to get an optimal result of the reconstruction. Reconstruction of the lower eyelid coloboma includes the use of a myocutaneous flap, which is elevated and in this manner closes the eyelid defect. External ear reconstruction is usually done when the individual is at least eight years old. Sometimes, the external auditory canal or middle ear can also be treated. The optimal age for the maxillomandibular reconstruction is controversial; as of 2004, this classification has been used: Type I (mild) and Type IIa (moderate) 13–16 years Type IIb (moderate to severe malformation) at skeletal maturity Type III (severe) 6–10 years When the teeth are cutting, the teeth should be under supervision of an orthodontist to make sure no abnormalities occur.
Sources: en.wikipedia.org
The Indian cobra (Naja naja) is a moderately venomous species, but has a rapid-acting venom. In mice, the SC LD50 for this species is 0.80 mg/kg and the average venom yield per bite is between 169 and 250 mg. Though it is responsible for many bites, only a small percentage are fatal if proper medical treatment and antivenom are given. The mortality rate for untreated bite victims can vary from case to case, depending upon the quantity of venom delivered and by the individual involved. According to one study, it is approximately 15–20% but in another study, with 1,224 bite cases, the mortality rate was only 6.5%. Estimated fatalities as a result of this species is approximately 15,000 per year, but they are responsible for an estimated 100,000–150,000 non-fatal bites per year.
In Koch's postulates, he set out criteria to test if an organism is the cause of a disease, and these postulates are still used today. Both Koch and Pasteur played a role in improving antisepsis in medical treatment. In 1870–1885 the modern methods of bacteriology technique were introduced by the use of stains, and by the method of separating mixtures of organisms on plates of nutrient media. Though it had been known since the nineteenth century that bacteria are a cause of many diseases, no effective antibacterial treatments were available until the 20th century. In 1910, Paul Ehrlich developed the first antibiotic, by changing dyes that selectively stained Treponema pallidum—the spirochaete that causes syphilis—into compounds that selectively killed the pathogen. Ehrlich was awarded a 1908 Nobel Prize for his work on immunology, and pioneered the use of stains to detect and identify bacteria, with his work being the basis of the Gram stain and the Ziehl–Neelsen stain. In the early 20th century, there was debate about the classification of bacteria. In 1904, cyanobacteria were usually classified as a class of algae, which are eukaryotic. However, Haeckel at this time classed cyanobacteria with bacteria because they lacked nuclei. In 1938, Herbert Faulkner Copeland proposed that prokaryotes be granted their own kingdom. The development of the transmission electron microscope allowed better visualization of cell structure and helped to clarify issues.
== Cell types and locations == The spleen is the second largest unit of the mononuclear phagocyte system. The monocyte is formed in the bone marrow and transported by the blood; it migrates into the tissues, where it transforms into a histiocyte or a macrophage. Macrophages are diffusely scattered in the connective tissue and in liver (Kupffer cells), spleen and lymph nodes (sinus histiocytes), lungs (alveolar macrophages), and central nervous system (microglia). The half-life of blood monocytes is about 1 day, whereas the life span of tissue macrophages is several months or years. The mononuclear phagocyte system is part of both humoral and cell-mediated immunity. The mononuclear phagocyte system has an important role in defense against microorganisms, including mycobacteria, fungi, bacteria, protozoa, and viruses. Macrophages remove senescent erythrocytes, leukocytes, and megakaryocytes by phagocytosis and digestion.
== History == In 1943, diphenhydramine was discovered by chemist George Rieveschl and one of his students, Fred Huber, while they were conducting research into muscle relaxants at the University of Cincinnati. Huber first synthesized diphenhydramine. Rieveschl then worked with Parke-Davis to test the compound, and the company licensed the patent from him. In 1946, it became the first prescription antihistamine in the United States approved by the FDA. In the 1960s, diphenhydramine was found to weakly inhibit reuptake of the neurotransmitter serotonin. This discovery led to a search for viable antidepressants with similar structures and fewer side effects, culminating in the invention of fluoxetine (Prozac), a selective serotonin reuptake inhibitor (SSRI). A similar search had previously led to the synthesis of the first SSRI, zimelidine, from brompheniramine, also an antihistamine. In 1975, diphenhydramine was still available only by prescription in the US and required medical supervision.
The fetal membranes are the four extraembryonic membranes associated with the developing embryo and fetus in humans and other mammals. They are the amnion, chorion, allantois, and yolk sac. The amnion and the chorion are the chorioamniotic membranes that make up the amniotic sac, which surrounds and protects the embryo. The fetal membranes are four of six accessory organs developed by the conceptus that are not part of the embryo itself; the other two are the placenta and the umbilical cord.
Sources: en.wikipedia.org
== Graphical summary == The chart below shows opinion polls conducted since the 2024 general election. The trend lines are local regressions (LOESS). The bar on the left represents the previous election, and the bar on the right represents the latest possible date of the next election.
=== Pharmacokinetics === Loxapine is metabolized to amoxapine, as well as its 8-hydroxy metabolite (8-hydroxyloxapine). Amoxapine is further metabolized to its 8-hydroxy metabolite (8-hydroxyamoxapine), which is also found in the blood of people taking loxapine. At steady-state after taking loxapine by mouth, the relative amounts of loxapine and its metabolites in the blood is as follows: 8-hydroxyloxapine > 8-hydroxyamoxapine > loxapine. The pharmacokinetics of loxapine change depending on how it is given. Intramuscular injections of loxapine lead to higher blood levels and area under the curve of loxapine than when it is taken by mouth.
Re-lactation is the process of restarting breastfeeding. In developing countries, mothers may restart breastfeeding after a weaning as part of an oral rehydration treatment for diarrhea. In developed countries, re-lactation is common after early medical problems are resolved, or because a mother changes her mind about breastfeeding. Re-lactation is most easily accomplished with a newborn or with a baby that was previously breastfeeding; if the baby was initially bottle-fed, the baby may refuse to suckle. If the mother has recently stopped breastfeeding, chances are higher that the milk supply will return and be adequate. Although some mothers successfully re-lactate after months-long interruptions, success is higher for shorter interruptions. Techniques to promote lactation include frequent attempts to breastfeed, extensive skin-to-skin contact with the baby, and frequent, long pumping sessions. Suckling may be encouraged with a tube filled with infant formula, so that the baby associates suckling at the breast with food. A dropper or syringe without the needle may be used to place milk onto the breast while the baby suckles. The mother should allow the infant to suckle at least ten times during 24 hours, and more times if the baby is interested. These times can include every two hours, whenever the baby seems interested, longer at each breast, and when the baby is sleepy, when they might suckle more readily. In keeping with increasing contact between mother and child, including increasing skin-to-skin contact, grandmothers should pull back and help in other ways.
With Fábregas breaking into the first team, Wenger chose to deviate from their counter-attacking style, to a more possession based one. In 2009–10, he instituted a fluid 4–3–3 formation to benefit from Fàbregas' creativity, and since the player's departure, had remodelled the system to 4–1–4–1 and 4–2–3–1. During the latter half of the 2016–17 Premier League season, Wenger switched to a 3–4–3 formation, similar to Antonio Conte's Chelsea first used against Middlesbrough in a 2–1 win. Wenger proved able to implement his entertaining vision of football, particularly at Arsenal. His team's 5–1 win against Portsmouth in March 2004 was likened to "the magnificently fluid Ajax of the early 70s", and greeted with a standing ovation by the opposition supporters, as the Arsenal players left the field. Wenger's style of play, however, has been criticised for inefficiency and a lack of variation to go with technique. He is not renowned for making game-changing substitutions, nor had his tactics helped his teams overcome flexible opponents. His ideals are noticeably different from the pragmatic approach of his rivals, though he has assembled teams to produce disciplined performances, markedly the 2005 FA Cup Final against Manchester United. Defeats in the big games during 2013–14 led to Wenger compromising his attack-minded principles in favour of keeping it tight.
==== 19 April ==== President Trump announced that the US had attacked the Iran-flagged cargo ship Touska after it attempted to breach the US naval blockade of Iran, blowing a hole in its engine room and taking the ship into custody. The vessel, almost 900 feet (270 m) long, was en route to Bandar Abbas. It was warned by the USS Spruance over a six-hour period before the destroyer fired several rounds from its 5-inch/54-caliber Mark 45 gun into the engine room, disabling it. It was then seized by the 31st Marine Expeditionary Unit in the Gulf of Oman. Iran described the seizure as a truce violation.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is normally kept frozen, desiccated, and away from light, with brief warming to room temperature before opening to limit condensation. Repeated freeze-thaw cycles are avoided because they stress the peptide. Once in solution, the material is held cold and used promptly.